Alvotech Champions Switching Data As Clock Ticks On Adalimumab Filing
Top-Line Results Announced In Major Switching Study; Bioequivalence Demonstrated
Before the month is out, Alvotech hopes to hear back from the US FDA for its AVT02 high-concentration 100mg/ml biosimilar adalimumab candidate. The Icelandic firm, which remains embroiled in litigation with originator AbbVie, has reported top-line results from its key switching study.
You may also be interested in...
Alvotech Reveals Action Date For Interchangeable Adalimumab BLA
While awaiting news from the FDA for its biosimilar application referencing the higher-concentration formulation of Humira, Alvotech has announced that the FDA has accepted its BLA supporting interchangeability for the AVT02 candidate.
Alvotech Differentiation Plans Include Interchangeable Golimumab
A proposal to merge with a special purpose acquisition company, in a move that will deliver longstanding plans for a public listing, has led biosimilars specialist Alvotech to discuss its ambitions and goals for its pipeline of seven biosimilar candidates.
Alvotech Eyes $450m Funding And Public Listing With SPAC Merger
Eight years after its inception, pure-play biosimilars company Alvotech has announced plans to list on the NASDAQ via a SPAC merger that will deliver hundreds of millions in cash to fund product development and future growth.